Effectiveness of biological targeted therapies may discriminate seronegative from seropositive rheumatoid arthritis
Study context
- Population
- Rheumatoid arthritis (RA) patients receiving abatacept, anti-TNF alpha or tocilizumab, by rheumatoid factor (RF)/anti-citrullinated protein antibodies (ACPA) serostatus
- Exposure
- Seronegative vs seropositive RA treated with abatacept, anti-TNF alpha or tocilizumab
- Seronegativen = 81
- Seropositiven = 404reference
- Outcome
- Drug survival (Kaplan-Meier), compared by log rank test
- Follow-up
- 10-year follow-up
Methodological detailsKaplan-Meier drug survival analysis, multivariate Cox regression
- Kaplan-Meier drug survival analysis
- Multivariate Cox regression
Main finding
As reported in the abstract
Drug survival in seronegative RA
| Group | Value | Mean survival time (MST) |
|---|---|---|
| Tocilizumab | 73.9% | 76.8 months (95% CI 61-92) |
| Abatacept | 37.5% | 37.1 months (95% CI 22-51 |
| Anti-TNF alpha | 50.0% | 63.5 months (95% CI 47-79) |
Value
Tocilizumab73.9%
Abatacept37.5%
Anti-TNF alpha50.0%
Mean survival time (MST)
Tocilizumab76.8 months (95% CI 61-92)
Abatacept37.1 months (95% CI 22-51
Anti-TNF alpha63.5 months (95% CI 47-79)
- Tocilizumab vs Abatacept: P = 0.01 — tocilizumab significantly higher
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Inadequate responders to prior bDMARDsSeronegative vs Seropositive · significantly higher percentage in seronegative | P = 0.02 |
Drug survival in seropositive RA
- Seropositive RA did not show significantly different drug survival rates across therapies
Predictors of drug discontinuation (multivariate Cox)
- RF/ACPA positivity, HR
- 0.56
- Male sex, HR
- 0.58
- Abatacept, HR
- 1.88
- Anti-TNF alpha, HR
- 1.79
- No co-therapy with csDMARDs, HR
- 1.74
- Absence of bone erosions, HR
- 1.41
- Higher HAQ, HR
- 1.58
Original publication
Effectiveness of biological targeted therapies may discriminate seronegative from seropositive rheumatoid arthritis. Rheumatology (Oxford). Published 22 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →